The ResApp app could detect COVID-19 by coughing on your smartphone

After more than two years of advice on where not to cough, a new note suggests that coughing into your smartphone might actually be helpful. A new smartphone app from ResApp Health Limited, an Australian health technology company, may be available soon Facilitate the process of detecting COVID-19 by asking people to cough into their smartphone. Like an analog solution from the past, ResApp uses machine learning to do this Analyze coughing habits and determining whether or not a person has the coronavirus.

In two clinical studies conducted on a total of 741 patients in the United States (NCT04864535) and India (CTRI/2021/09/036581), ResApp was able to diagnose COVID-19 with an accuracy of 92%. The company offers this immediate, non-invasive method of screening for COVID-19 ahead of other forms of testing that require swabs from a person’s mouth or nasal cavity. It can be a great option for places that require frequent testing, such as shopping malls, hospitals, offices, sporting events, and other public places that draw large numbers of visitors.

The company claims so The test takes less than 30 seconds and that it delivers results without no environmental hazard from organic waste generated by other test forms. ResApp also has the potential to avoid a significant amount of logistics costs and hassles typically associated with traditional testing.

Medical researchers are still looking for quick — but more importantly, reliable — ways to detect COVID-19. The two most commonly used methods today to detect the presence of COVID-19 in patients are the rapid antigen test (RAT) and a technique known as real-time reverse transcription – chain reaction by polymerase (RT-PCR).

Easy and quick detection

The RAT test detects antigens in a person’s nasal cavity – COVID-19 self-test kits use the RAT method. Using RT-PCR is not as fast as the simpler RAT method, but this more comprehensive test is more accurate. RT-PCR screens a sample for specific genetic markers of COVID-19, giving health officials and patients a clear idea of ​​whether treatment is needed. According to ResApp Health Limited, tests conducted on their app showed the sensitivity that “exceeds the sensitivity of rapid antigen tests measured in practice“.

The combination of high sensitivity and 80% specificity allows 8 out of 10 people without COVID-19 to be correctly screened as negative and require no subsequent antigen or PCR testing», called a representative of ResApp Health Limited in a statement.

Although the app can tell if someone has been infected with COVID-19, It cannot recognize the variant of the virus that the person has contracted. However, the company says the app has consistently detected COVID-19 during outbreaks of the Omicron and Delta variants. The results of the study have not yet been published in any medical journal or submitted for peer review. Once this is done, we will have a more credible analysis of the application’s reliability.

Pfizer approached ResApp Health Limited about an acquisition

Meanwhile, pharmaceutical giant Pfizer has approached ResApp Health Limited for a takeover proposal worth around $75 million. Corresponding 9News, Pfizer Australia is expected to acquire 100% of ResApp stock for approximately $0.084 per share. ResApp also has several other apps that can detect respiratory diseases simply by monitoring a person’s respiratory characteristics.

Since Pfizer pumped funds into the development of the app, we could see improvements and adoption around the world in a very short time.

Leave a Reply

Your email address will not be published.